March 18, 2026
Sit, wait listen after Tuesday closed off highs of the session
Fed’s interest rate decision expected to keep interest rates unchanged in a range between 3.5% to 3.75%
Pre-open Signals: 5 Positive Indications
Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.
Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!
March 19, 2026
3/19 - Harvard Apparatus RT (OTCQB: HRGN dived -0.28 or -16.67% to $1.40 on 1 share traded
... after Wednesday’s $0.00 after Tuesday’s a.m., drop -$0.37 and closing down -$0.04 with 4,985 shares traded after barely trading lately)
Reinforces Ponzi Scheme!
Financing ... (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity”
Such a deal, next joke!
Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company!
WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND
March 18, 2026
How many times, have I written the obvious as I wrote this a.m., markets and the C> sector trades with hesitation
Also, as I wrote expectantly, “The Fed kept its fed funds rate in a range between 3.5% to 3.75%”
The level of hedging is intense, unfulfilled and nor forgiving as wholesale prices rose 0.7% in February, much more than expected and up 3.4% annually
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision
Never leave a retail investor uninformed! It’s not always time to buy or sell; but it is time to KNOW why!
March 19, 2026
3/19 - Harvard Apparatus RT (OTCQB: HRGN dived -0.28 or -16.67% to $1.40 on 1 share traded ... after Wednesday’s $0.00 after Tuesday’s a.m., drop -$0.37 and closing down -$0.04 with 4,985 shares traded after barely trading lately) Reinforces Ponzi Scheme! Financing ... (Notice of Exempt Offering of Securities); who or what US institution would invest in this “entity” Entered into Securities Purchase Agreements with Investors agreeing to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $700 K and a purchase price per share of $1.70. A cheap date; WHY hasn’t Beijing, China stepped-up???? While ... broke and seriously in debt to partners, how long will these $$ last? Such a deal, next joke! Broke, no patient data in 4 years, questionable management, serious unpaid bills in hundreds of thousands to partners and employees past and present; even was sued and had to pay for a patient DEATH, usually a death knell foe any company! Guess who's providing the lipstick for this pig! WHO and WHAT is its owner ... a Beijing, China percentage (%) “owned”, financed and run company … with patterns of share pricing manipulation? Cash starved, NO clinical data after 5-year ago IND Accumulated deficit to date = $103.2 M in 12 years ... U.S. investors BEWARE, forewarned is forearmed?
March 8, 2026
14.9 M shares priced at $5.61 with a positive +$0.15 or +2.22% Monday pre-open Oversubscribed, 3/6/26 The private placement was anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others.
February 15, 2026
A scorecard of covered companies Q4/25 and FY254 net losses or incomes correlated to EPS leanings of per share value, cash positions and “runways”, financials outcomes and correlation of "street" expectations - it's a reflection of this universe's investing "status" I have written what I as an investor would want to know … Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
